CD95/Fas and metastatic disease: What does not kill you makes you stronger - Université de Rennes Access content directly
Journal Articles Seminars in Cancer Biology Year : 2020

CD95/Fas and metastatic disease: What does not kill you makes you stronger

Abstract

CD95 (also known as Fas) is the prototype of death receptors; however, evidence suggests that this receptor mainly implements non-apoptotic signaling pathways such as NF-κB, MAPK, and PI3K that are involved in cell migration, differentiation, survival, and cytokine secretion. At least two different forms of CD95 L exist. The multi-aggregated transmembrane ligand (m-CD95 L) is cleaved by metalloproteases to release a homotrimeric soluble ligand (s-CD95 L). Unlike m-CD95 L, the interaction between s-CD95 L and its receptor CD95 fails to trigger apoptosis, but instead promotes calcium-dependent cell migration, which contributes to the accumulation of inflammatory Th17 cells in damaged organs of lupus patients and favors cancer cell invasiveness. Novel inhibitors targeting the pro-inflammatory roles of CD95/CD95 L may provide attractive therapeutic options for patients with chronic inflammatory disorders or cancer. This review discusses the roles of the CD95/CD95 L pair in cell migration and metastasis.
Fichier principal
Vignette du fichier
Legembre_et al_CD95 Fas and metastatic disease_accepted.pdf (1.54 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-02179928 , version 1 (12-09-2019)

Identifiers

Cite

Jean Philippe Guégan, Christophe Ginestier, Emmanuelle Charafe-Jauffret, Thomas Ducret, Jean-François Quignard, et al.. CD95/Fas and metastatic disease: What does not kill you makes you stronger. Seminars in Cancer Biology, 2020, 60, pp.121-131. ⟨10.1016/j.semcancer.2019.06.004⟩. ⟨hal-02179928⟩
448 View
746 Download

Altmetric

Share

Gmail Facebook X LinkedIn More